企業治験 | ||
主たる治験と拡大治験のいずれにも該当しない | ||
令和元年7月17日 | ||
令和5年11月19日 | ||
転移性または切除不能な非小細胞肺癌患者を対象としたU3-1402の多施設共同非盲検第I相試験 | ||
非小細胞肺癌患者を対象としたU3-1402の第I相試験 | ||
第一三共株式会社 | ||
本試験はU3-1402の安全性及び有効性を評価するために、用量漸増パートと用量展開パートから構成される。用量漸増パートでは、上皮成長因子受容体(epidermal growth factor receptor: EGFR)チロシンキナーゼ阻害剤(tyrosine kinase inhibitor: TKI)による治療中又は治療後に病勢の進行が認められた、EGFR活性化変異を有する転移性又は切除不能なNSCLC患者を対象に、U3-1402を評価する。用量展開パートでは、局所進行又は転移性疾患に対する全身治療中又は全身治療後に病勢の進行が認められた、転移性又は切除不能なEGFR活性化変異を有するNSCLC、又は扁平上皮又は非扁平上皮(すなわち、EGFR活性化異を有しない)NSCLCの患者を対象に、U3-1402を評価する。 | ||
1 | ||
非小細胞肺癌 | ||
参加募集終了 | ||
U3-1402、- | ||
近畿大学病院 治験審査委員会 | ||
試験等の種別 | 企業治験 |
---|---|
主たる治験と拡大治験のいずれにも該当しない | |
登録日 | 2023年11月13日 |
jRCT番号 | jRCT2080224788 |
転移性または切除不能な非小細胞肺癌患者を対象としたU3-1402の多施設共同非盲検第I相試験 | A MULTICENTER, OPEN-LABEL PHASE 1 STUDY OF U3-1402 IN SUBJECTS WITH METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER | ||
非小細胞肺癌患者を対象としたU3-1402の第I相試験 | A PHASE 1 STUDY OF U3-1402 IN SUBJECTS NON-SMALL CELL LUNG CANCER |
第一三共株式会社 | DAIICHI SANKYO Co.,Ltd. | ||
臨床試験情報公開窓口 | |||
東京都品川区広町1-2-58 | 1-2-58, Hiromachi, Shinagawa-ku, Tokyo | ||
03-6225-1111 | |||
dsclinicaltrial@daiichisankyo.co.jp |
第一三共株式会社 | DAIICHI SANKYO Co.,Ltd. | ||
臨床試験情報公開窓口 | |||
1-2-58, Hiromachi, Shinagawa-ku, Tokyo | 1-2-58, Hiromachi, Shinagawa-ku, Tokyo | ||
03-6225-1111 | |||
dsclinicaltrial@daiichisankyo.co.jp |
2019年10月21日 |
/ |
|
|
|
---|---|---|---|
/ | |||
|
|||
本試験はU3-1402の安全性及び有効性を評価するために、用量漸増パートと用量展開パートから構成される。用量漸増パートでは、上皮成長因子受容体(epidermal growth factor receptor: EGFR)チロシンキナーゼ阻害剤(tyrosine kinase inhibitor: TKI)による治療中又は治療後に病勢の進行が認められた、EGFR活性化変異を有する転移性又は切除不能なNSCLC患者を対象に、U3-1402を評価する。用量展開パートでは、局所進行又は転移性疾患に対する全身治療中又は全身治療後に病勢の進行が認められた、転移性又は切除不能なEGFR活性化変異を有するNSCLC、又は扁平上皮又は非扁平上皮(すなわち、EGFR活性化異を有しない)NSCLCの患者を対象に、U3-1402を評価する。 | This study is designed to evaluate safety and antitumor activity of U3-1402 in two parts: Dose Escalation and Dose Expansion. In Dose Escalation, U3-1402 will be evaluated in participants with metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation after disease progression during/after EGFR tyrosine kinase inhibitor (TKI) therapy. In Dose Expansion, U3-1402 will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCLC (ie, without EGFR-activating mutations) with disease progression during/after systemic treatment for locally advanced or metastatic disease. | ||
1 | 1 | ||
2019年11月20日 | |||
2017年10月30日 | |||
2024年12月31日 | |||
264 | |||
介入研究 | Interventional | ||
主要目的はそれぞれ以下のとおりである。 用量漸増パートについては、U3-1402の安全性及び忍容性を評価し、また、U3-1402の用量展開推奨用量(recommended dose for expansion: RDE)を決定する。 用量展開パートについては、U3-1402の有効性を検討する。 本治験では、治療サイクル数は固定されていない。参加者は、中断(同意撤回)、病勢の進行(progressive disease: PD)、または副作用が許容できなくなる(許容できない毒性)、またはその他の中止理由に抵触するまで、治験治療を継続する(約36ヵ月間)。 |
The primary objectives are: For Dose Escalation, to assess the safety and tolerability of U3-1402 in the study population and to determine the recommended dose for expansion (RDE) of U3-1402 in the study population For Dose Expansion, to investigate the antitumor activity of U3-1402 The number of treatment cycles is not fixed in this study. Participants will continue study treatment (for approximately 36 months) until they decide not to (withdraw consent), their disease gets worse [progressive disease (PD)], or side effects become unacceptable (unacceptable toxicity) or other stopping reasons have been met. |
||
治療 |
treatment purpose |
||
/ | 日本/アジア(日本以外)/北米/欧州 | Japan/Asia except Japan/North America/Europe | |
/ | 用量漸増パート及び用量展開パートに共通の選択基準 |
Inclusion Criteria for both Dose Escalation and Dose Expansion: |
|
/ | 用量漸増パート及び用量展開パートに共通の除外基準 |
Exclusion Criteria for Dose Escalation and Dose Expansion: |
|
/ | 18歳以上 |
18age old over |
|
/ | 上限なし |
No limit |
|
/ | 男性・女性 |
Both |
|
/ | 非小細胞肺癌 | Non-small Cell Lung Cancer | |
/ | |||
/ | 試験対象薬剤等 一般的名称等:U3-1402 薬剤・試験薬剤:- 薬効分類コード:429 その他の腫瘍用薬 用法・用量、使用方法:点滴静注 対象薬剤等 一般的名称等:- 薬剤・試験薬剤:- 薬効分類コード: 用法・用量、使用方法:- |
investigational material(s) Generic name etc : U3-1402 INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : intravenous control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : - |
|
/ | |||
/ | 安全性 有効性 1. 用量漸増パートでの用量制限毒性(Dose Limiting Toxicities: DLT)[期間:Cycle 1の21日間] 2. 用量漸増パートでの有害事象の要約[期間:全世界での試験終了日まで、約36ヵ月以内] 3. 用量展開パートでの独立中央審査(Blinded Independent Central Review: BICR)の評価に基づく奏効率(Objective response rate: ORR)[期間:約36ヵ月以内]。評価はRECIST 1.1に基づく。 4. 用量展開パートでのU3-1402、総抗HER3 抗体及びMAAA-1181aの最高血清/血漿中濃度(maximum [peak]observed concentration in serum: Cmax)(コホート4のみ)。[期間:Cycle 1: Day 1の投与前、点滴静注終了(end of infusion: EOI)、EOIの2時間後、4時間後及び8時間後、Day 8、Day 15。Cycle 2: Day 1の投与前。(各cycle 21日間)]。 5. 用量展開パートでのU3-1402、総抗HER3 抗体及びMAAA-1181aの血清中濃度-時間曲線下面積(area under the serum concentrationtime curve from time 0 to infinite time: AUCinf)及び定量可能な最終時点までの血清中濃度-時間曲線下面積(area under the serum concentrationtime curve up to the last quantifiable time: AUClast)(コホート4のみ)[期間: Cycle 1: Day 1の投与前、EOI、EOIの2時間後、4時間後及び8時間後、Day 8、Day 15。Cycle 2: Day 1の投与前。(各cycle 21日間)]。 |
safety efficacy 1. Dose-limiting toxicities (DLTs) during dose escalation [Time Frame: 21 days of Cycle 1] 2. Summary of adverse events during dose escalation [Time Frame: By the global end of trial date, approximately within 36 months] 3. Overall response rate (ORR) assessed by Blinded Independent Central Review (BICR) Committee during dose expansion [Time Frame: Approximately within 36 months] ORR will be evaluated using RECIST v1.1. 4. Maximum serum concentration (Cmax) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose expansion (Cohort 4) [Time Frame: Cycle 1: Day 1, pre-dose and end of infusion (EOI), 2 hours, 4 hours, 8 hours; Day 8, Day 15; Cycle 2: Day 1, pre-dose (each cycle is 21 days)] 5. Area under the serum concentration-time curve from time 0 extrapolated to infinity (AUCinf) and up to last quantifiable time (AUC[last]) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose expansion (Cohort 4) [Time Frame: Cycle 1: Day 1, pre-dose and end of infusion (EOI), 2 hours, 4 hours, 8 hours; Day 8, Day 15; Cycle 2: Day 1, pre-dose (each cycle is 21 days)] |
|
/ | 安全性 有効性 探索性 薬物動態 薬力学 ファーマコゲノミクス 1. 用量漸増パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aの最高血清中濃度(Maximum [peak] observed plasma concentration: Cmax)[期間:初回投与から約84日間] 2. 用量漸増パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aの最高濃度到達時間(Time to reach maximum observed concentration: Tmax)[期間:初回投与から約84日間] 3. 用量漸増パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aの投与後8時間までの血清中濃度-時間曲線下面積(area under the serum concentration-time curve from time 0 to 8 hours: AUC8h)、及び定量可能な最終時点までの血清中濃度-時間曲線下面積(area under the serum concentration-time curve up to the last quantifiable time: AUClast)[期間:初回投与から約84日間] 4. 用量漸増パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aの消失速度定数(the terminal elimination rate constant: Kel)[期間:初回投与から約84日間] 5. 用量漸増パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aの消失半減期(elimination half-life: t1/2)[期間:初回投与から約84日間] 6. 用量漸増パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aの全身クリアランス(total body clearance: CL)[期間:初回投与から約84日間] 7. 用量漸増パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aの単回投与後の分布容積(volume of distribution after a single dose: Vz)、及び反復投与後の定常状態の見かけの分布容積(apparent volume of distribution at steady-state after multiple dose: Vss)[期間:初回投与から約84日間] 8. 用量漸増パートでのORR[期間:約36ヶ月以内]評価はRECIST 1.1に基づく 9. 用量漸増パートでの病勢コントロール率(Disease control rate: DCR)[期間:約36ヶ月以内] 10. 用量漸増パートでの奏効期間(Duration of response: DOR)[期間:約36ヶ月以内] 11. 用量漸増パートでの効果発現までの期間(Time to response: TTR)[期間:約36ヶ月以内] 12. 用量漸増パートでの無増悪生存期間(Progression-free survival: PFS)[期間:約36ヶ月以内] 13. 用量漸増パートでの全生存期間(Overall survival: OS)[期間:約36ヶ月以内] 14. 用量展開パートでの有害事象の要約[期間:全世界での試験終了日まで、約36ヵ月以内] 15. 用量展開パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aのCmax[期間:初回投与から約84日間] 16. 用量展開パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aのTmax[期間:初回投与から約84日間] 17. 用量展開パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aのAUC8h、AUC0-21d及びAUClast[期間:初回投与から約84日間] 18. 用量展開パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aのKel[期間:初回投与から約84日間] 19. 用量展開パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aのt1/2[期間:初回投与から約84日間] 20. 用量展開パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aのCL[期間:初回投与から約84日間] 21. 用量展開パートでのU3-1402、総抗HER3抗体、及びMAAA-1181aのVz、及びVss[期間:初回投与から約84日間] 22. 用量展開パートでのORR[期間:約36ヶ月以内]評価はRECIST 1.1に基づく 23. 用量展開パートでのDCR[期間:約36ヶ月以内] 24. 用量展開パートでのDOR[期間:約36ヶ月以内] 25. 用量展開パートでのTTR[期間:約36ヶ月以内] 26. 用量展開パートでのPFS[期間:約36ヶ月以内] 27. 用量展開パートでのOS[期間:約36ヶ月以内] 28. 用量展開パート(コホート4)における抗薬物抗体(ADA)陽性(ベースラインおよびベースライン後)の発現率、および治療下におけるADA発現率[期間:約36ヶ月以内] |
safety efficacy exploratory pharmacokinetics pharmacodynamics pharmacogenomics 1. Maximum serum concentration (Cmax) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose escalation [ Time Frame: During approximately the first 84 days after dosing] 2. Time of maximum concentration (Tmax) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose escalation [ Time Frame: During approximately the first 84 days after dosing] 3. Area under the serum concentration-time curve from time 0 to 8 hours (AUC[0-8]) and up to last quantifiable time (AUC[last]) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose escalation [Time Frame: During approximately the first 84 days after dosing] 4. Terminal elimination rate constant (Kel) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose escalation [Time Frame: During approximately the first 84 days after dosing] 5. Elimination half-life (t1/2) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose escalation [Time Frame: During approximately the first 84 days after dosing] 6. Total body clearance (CL) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose escalation [Time Frame: During approximately the first 84 days after dosing] 7. Volume of distribution after a single-dose (Vz) and at steady-state after multiple doses (Vss) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose escalation [Time Frame: During approximately the first 84 days after dosing] 8. Overall response rate (ORR) during dose escalation [Time Frame: Approximately within 36 months] Evaluated using RECIST 1.1 9. Disease control rate (DCR) during dose escalation [Time Frame: Approximately within 36 months] 10. Duration of response (DOR) during dose escalation [Time Frame: Approximately within 36 months] 11. Time to response (TTR) during dose escalation [Time Frame: Approximately within 36 months] 12. Progression free survival (PFS) during dose escalation [Time Frame: Approximately within 36 months] 13. Overall Survival (OS) during dose escalation [Time Frame: Approximately within 36 months] 14. Summary of adverse events during dose expansion [Time Frame: By the global end of trial date, approximately within 36 months] 15. Maximum serum concentration (Cmax) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose expansion [Time Frame: During approximately the first 84 days after dosing] 16. Time of maximum concentration (Tmax) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose expansion [Time Frame: During approximately the first 84 days after dosing] 17. Area under the serum concentration-time curve from time 0 to 8 hours (AUC[0-8]), from time 0 to Day 21 (AUC-21d), and up to last quantifiable time (AUC[last]) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose expansion [Time Frame: During approximately the first 84 days after dosing] 18. Terminal elimination rate constant (Kel) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose expansion [Time Frame: During approximately the first 84 days after dosing] 19. Elimination half-life (t1/2) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose expansion [Time Frame: During approximately the first 84 days after dosing] 20. Total body clearance (CL) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose expansion [Time Frame: During approximately the first 84 days after dosing] 21. Volume of distribution after a single-dose (Vz) and at steady-state after multiple doses (Vss) of U3-1402, total anti-HER3 antibody, and MAAA 1181a during dose expansion [Time Frame: During approximately the first 84 days after dosing] 22. Overall response rate (ORR) during dose expansion [Time Frame: Approximately within 36 months] Evaluated using RECIST 1.1 23. Disease control rate (DCR) during dose expansion [Time Frame: Approximately within 36 months] 24. Duration of response (DOR) during dose expansion [Time Frame: Approximately within 36 months] 25. Time to response (TTR) during dose expansion [Time Frame: Approximately within 36 months] 26. Progression free survival (PFS) during dose expansion [Time Frame: Approximately within 36 months] 27. Overall survival (OS) during dose expansion [Time Frame: Approximately within 36 months] 28. Percentage of participants who are anti-drug antibody (ADA)-positive (baseline and post-baseline) and Percentage of participants who have treatment-emergent ADA during dose expansion (Cohort 4) [Time Frame: Approximately within 36 months] |
医薬品 | medicine | |||
U3-1402 | ||||
- | - | |||
429 その他の腫瘍用薬 | 429 Other antitumor agents | |||
点滴静注 | ||||
- | ||||
- | - | |||
- |
参加募集終了 | completed | |
/ | 実施中 |
progressing |
第一三共株式会社 | ||
DAIICHI SANKYO Co.,Ltd. |
- | ||
- | ||
- |
近畿大学病院 治験審査委員会 | Clinical Trial Review Board of Kindai University Hospital | |
大阪府大阪狭山市大野東377-2 | 377-2, Ohnohigashi, Osaka-Sayama City, Osaka Prefecture, Japan, Osaka | |
072-366-0221 | ||
承認 | approved |
有 | presence | |
NCT03260491 | ||
ClinicalTrials.gov | ClinicalTrials.gov | |
JapicCTI-194868 | ||
有 | Yes | ||
概要: 終了した試験の非特定化された個別被験者データ(IPD)及び関連文書を、データ共有サイトhttps://vivli.org/ で要求することができる。臨床試験データと関連文書は、第一三共のデータ共有ポリシーと手順に基づき提供され、被験者の個人情報は保護される。以下のウェブサイトに、データ共有の条件とデータへのアクセス申請の手順を示す。 https://vivli.org/ourmember/daiichi-sankyo/ 関連文書: - 治験実施計画書 - 統計解析計画書(SAP) - 同意説明文書(ICF) データの共有が可能となる時期: 試験が終了しすべてのデータが収集・解析され、米国、欧州、日本で予定された当該医薬品もしくは適応症の承認(2014 年 1 月 1 日以降の承認)が得られ、主要な結果を学会等に公表後。 データへのアクセス条件: 2014年1月1日以降に米国、欧州、日本で承認を取得した製品に関する、終了した臨床試験のIPD及び関連文書についての、資格を有した科学研究者又は医学研究者からの要求であり、研究目的であること。被験者の個人情報保護の原則を満たし、インフォームド・コンセントの規定内であること。 URL: https://vivli.org/ourmember/daiichi-sankyo/ | De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/ Supporting Information: - Study Protocol - Statistical Analysis Plan (SAP) - Informed Consent Form (ICF) Time Frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication. Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent. URL: https://vivli.org/ourmember/daiichi-sankyo/ |
Other Study ID Numbers: U31402-A-U102 | Other Study ID Numbers: U31402-A-U102 | ||
- 目標症例数: 用量漸増パート:約36名 用量展開パート:約228名 - IRB等に関する事項: 日本におけるIRBについて記載 | |||
設定されていません |
||
設定されていません |